Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Regenerative effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) after sequestrectomy of medication-related osteonecrosis of the jaw (MRONJ)

  • Min, Song-Hee (Department of Oral and Maxillofacial Surgery, Institute of Oral Health Science, Ajou University School of Medicine) ;
  • Kang, No-Eul (Department of Oral and Maxillofacial Surgery, Institute of Oral Health Science, Ajou University School of Medicine) ;
  • Song, Seung-Il (Department of Oral and Maxillofacial Surgery, Institute of Oral Health Science, Ajou University School of Medicine) ;
  • Lee, Jeong-Keun (Department of Oral and Maxillofacial Surgery, Institute of Oral Health Science, Ajou University School of Medicine)
  • Received : 2019.10.16
  • Accepted : 2020.02.25
  • Published : 2020.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Beyond the original application approved by the U.S. Food and Drug Administration, recombinant human bone morphogenetic protein-2 (rhBMP-2) is used for medication-related osteonecrosis of the jaw (MRONJ) treatment because of its bone remodeling enhancement properties. The purpose of the study was to investigate the bone formation effect of rhBMP-2/absorbable collagen sponge (ACS) in patients with MRONJ. Materials and Methods: In this retrospective cohort study, 26 female patients diagnosed with MRONJ and who underwent mandibular sequestrectomy at Ajou University Dental Hospital from 2010 to 2018 were included. The experimental group was composed of 18 patients who received rhBMP-2/ACS after sequestrectomy, while the control group was composed of 8 patients who did not receive rhBMP-2/ACS after sequestrectomy. A total dose of 0.5 mg of rhBMP-2 was used in the experimental group at a concentration of 0.5 mg/mL. Follow-up panoramic X-rays were taken immediately after the surgery and more than 6 months after the surgery. Using those X-rays, a radiographic index of bone defect area was calculated using the modified Ihan Hren method, which measures radiographic density of the normal bone and the defect site. Results: This study suggests that rhBMP-2 contributes to new bone formation. The mean radiographic index immediately after surgery and more than 6 months after the surgery for the experimental group was 68.4% and 79.8%, respectively. The mean radiographic index immediately after surgery and more than 6 months after the surgery for the control group was 73.4% and 76.7%, respectively (Wilcoxon signed rank test, P>0.05). The mean radiographic index increased 11.4% in the experimental group and 3.27% in the control group (Mann-Whitney U-test, P<0.05). Conclusion: Based on the results, use of rhBMP-2/ACS on bone defect sites after sequestrectomy could be a successful strategy for treatment of MRONJ patients.

Keywords

References

  1. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13. https://doi.org/10.5125/jkaoms.2013.39.1.9
  2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  3. Gomez Font R, Martinez Garcia ML, Olmos Martinez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal 2008;13:E318-24.
  4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009;35:119-30. https://doi.org/10.1111/j.1747-4477.2009.00213.x
  5. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent 2014;2014:107690. https://doi.org/10.1155/2014/107690
  6. Cicciu M, Herford AS, Juodzbalys G, Stoffella E. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg 2012;23:784-8. https://doi.org/10.1097/SCS.0b013e31824dbdd4
  7. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 2009;45:551-4. https://doi.org/10.1016/j.oraloncology.2009.01.002
  8. Park JH, Kim JW, Kim SJ. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2017;75:1176-84. https://doi.org/10.1016/j.joms.2016.12.005
  9. Freitas RM, Spin-Neto R, Marcantonio Junior E, Pereira LA, Wikesjo UM, Susin C. Alveolar ridge and maxillary sinus augmentation using rhBMP-2: a systematic review. Clin Implant Dent Relat Res 2015;17 Suppl 1:e192-201. https://doi.org/10.1111/cid.12156
  10. Carter TG, Brar PS, Tolas A, Beirne OR. Off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg 2008;66:1417-25. https://doi.org/10.1016/j.joms.2008.01.058
  11. Hwang DY, On SW, Song SI. Bone regenerative effect of recombinant human bone morphogenetic protein-2 after cyst enucleation. Version 2. Maxillofac Plast Reconstr Surg 2016;38:22. https://doi.org/10.1186/s40902-016-0070-4
  12. Chenard KE, Teven CM, He TC, Reid RR. Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized stem cell therapy. J Biomed Biotechnol 2012;2012:601549.
  13. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001;19:255-65. https://doi.org/10.1016/S0167-7799(01)01665-1
  14. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 2003;55:1613-29. https://doi.org/10.1016/j.addr.2003.08.010
  15. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59. https://doi.org/10.1007/s00198-007-0540-8
  16. Ihan Hren N, Miljavec M. Spontaneous bone healing of the large bone defects in the mandible. Int J Oral Maxillofac Surg 2008;37:1111-6. https://doi.org/10.1016/j.ijom.2008.07.008
  17. Yim JH, Lee JH. Panoramic analysis about spontaneous bone regeneration after enucleation of jaw cyst. J Korean Assoc Maxillofac Plast Reconstr Surg 2009;31:229-36.

Cited by

  1. Progress and Prospects of Polymer-Based Drug Delivery Systems for Bone Tissue Regeneration vol.12, pp.12, 2020, https://doi.org/10.3390/polym12122881
  2. Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review vol.10, pp.19, 2021, https://doi.org/10.3390/jcm10194480
  3. Recombinant Proteins-Based Strategies in Bone Tissue Engineering vol.12, pp.1, 2020, https://doi.org/10.3390/biom12010003